Rifampicin plus pyrazinamide versus isoniazid for treating latent tuberculosis infection: A meta-analysis

International Journal of Tuberculosis and Lung Disease

Volumn 10, Issue 10, 2006, Pages 1080-1090

  Gao, X F ^a   Wang, L ^a   Liu, G J ^a   Wen, J ^a   Sun, X ^a   Xie, Y ^a   Li, You Ping ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Isoniazid; Meta analysis; Pyrazinamide; Rifampicin; Tuberculosis

Indexed keywords

ISONIAZID; PYRAZINAMIDE; RIFAMPICIN;

ATTRIBUTABLE RISK; CLINICAL TRIAL; CONFIDENCE INTERVAL; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LIVER TOXICITY; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; SYSTEMATIC REVIEW; TUBERCULOSIS;

ANTIBIOTICS, ANTITUBERCULAR; ANTITUBERCULAR AGENTS; COMORBIDITY; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HUMANS; ISONIAZID; LIVER; PYRAZINAMIDE; RANDOMIZED CONTROLLED TRIALS; RIFAMPIN; RISK ASSESSMENT; TUBERCULOSIS;

EID: 33749465325     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Fountain F F, Tolley E, Chrisman C R, Self T H. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005; 128: 116-123.
2. Kopanoff D E, Snider D E Jr, Caras G J. Isoniazid-related hepatitis: a US Public Health Service cooperative surveillance study. Am Rev Respir Dis 1978; 117: 991-1001.
3. Snider D E Jr, Caras G J. Isoniazid-associated hepatitis death: a review of available information. Am Rev Respir Dis 1992; 145: 494-497.
4. Tulsky J P, Pilote L, Hahn J A, et al. Adherence to isoniazid prophylaxis in the homeless: a randomized controlled trial. Arch Intern Med 2000; 160: 697-702.
5. American Thoracic Society, Centers for Disease Control and Prevention. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161 (Suppl): S221-S247.
6. Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: New York and Georgia, 2000. Morb Mortal Wkly Rep 2001; 50: 289-291.
7. Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations: United States, 2001. Morb Mortal Wkly Rep 2001; 50: 733-735.
8. Centers for Disease Control and Prevention. Update: fatal and severe liver injuries associated with rifampin and pyrazinamide treatment for latent tuberculosis infection. Morb Mortal Wkly Rep 2002; 51: 998-999.
9. Centers for Disease Control and Prevention. Update: adverse event data and revised American Thoracic Society/CDC recommendations against the use of Rifampin and Pyrazinamide for treatment of latent tuberculosis infection-United States, 2003. Morb Mortal Wkly Rep 2003; 52: 735-738.
10. Juni P, Altman D G, Egger M. Systematic reviews in health care: assessing the quality of controlled clinical trials. BMJ 2001; 323: 42-46.
11. Alderson P, Green S, Higgins JPT. Cochrane Reviewers' Handbook 4.2.2 [updated March 2004]. In: The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd, 2004.
12. Halsey N A, Coberly J S, Desormeaux J, et al. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection. The Lancet 1998; 351: 786-792.
13. Mwinga A, Hosp M, Godfrey-Faussett P, et al. Twice weekly tuberculosis preventive therapy in HIV infection in Zambia. AIDS 1998; 12: 2447-2457.
14. Gordin F, Chaisson R E, Matts J P, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA 2000; 283: 1445-1450.
15. Jasmer R M, Saukkonen J J, Blumberg H M, et al. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann Intern Med 2002; 137: 640-647.
16. Leung C C, Law W S, Chang K C, et al. Initial experience on rifampin and pyrazinamide vs isoniazid in the treatment of latent tuberculosis infection among patients with silicosis in Hong Kong. Chest 2003; 124: 2112-2118.
17. Tortajada C, Martinez-Lacasa J, Sanchez F, et al. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus? Int J Tuberc Lung Dis 2005; 9: 276-281.
18. Ena J, Valls V. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis. Clin Infect Dis 2005; 40: 670-676.
19. The European Agency for the Evaluation of Medicinal Products. Evaluation of medicines for human use: points to consider on the choice of non-inferiority margin.: http://www.emea.eu.int/pdfs/ human/ewp/215899en.pdf. Accessed June 2006.
20. Higgins JPT, Thompson S G, Deeks J J, Altman D G. Measuring inconsistency in meta-analysis. BMJ 2003; 327: 557-560.
21. Sterne JAC, Egger M, Smith G D. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. BMJ 2001; 323: 101-105.
22. Woldehanna S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. The Cochrane Library, Issue 1, 2004. Chichester, UK: John Wiley & Sons, Ltd, 2004.
23. Anonymous. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis. Bull World Health Organ 1982; 60: 555-564.
24. Bock N N, Rogers T, Tapia J R, Herron G D, DeVoe B, Geiter L J. Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates. Chest 2001; 119:833-837.
25. Chaisson R E, Armstrong J, Stafford J, Golub J, Bur S. Safety and tolerability of intermittent rifampin/pyrazinamide for the treatment of latent tuberculosis infection in prisoners. JAMA 2002; 288: 165-166.
26. Lee A M, Mennone J Z, Jones R C, Paul W S. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis 2002; 6: 995-1000.
27. McNeill L, Allen M, Estrada C, Cook P. Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis. Chest 2003; 123: 102-106.
28. Stout J E, Engemann J J, Cheng A C, Fortenberry E R, Hamilton C D. Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis. Am J Respir Crit Care Med 2003; 167: 824-827.
29. Priest D H, Vossel L F, Sherfy E A, Hoy D P, Haley C A. Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program. Clin Infect Dis 2004; 39: 1764-1771.
30. Lobato M N, Reves R R, Jasmer R M, et al. Adverse events and treatment completion for latent tuberculosis in jail inmates and homeless persons. Chest 2005; 127: 1296-1303.
31. Saukkonen J. Rifampin and pyrazinamide for latent tuberculosis infection: clinical trials and general practice. Clin Infect Dis 2004; 39: 566-568.
32. McElroy P D, Ijaz K, Lambert L A, et al. National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2005; 41: 1125-1133.
33. Ijaz K, Jereb J A, Lambert L A, et al. severe or fatal liver injury in 50 patients in the united states taking rifampin and pyrazinamide for latent tuberculosis infection. Clin Infect Dis 2006; 42: 346-355.
34. Schulz K F, Chalmers I, Grimes D A, Altman D G. Assessing the quality of randomization from reports of controlled trials published in obstetrics and gynecology. JAMA 1994; 272: 125-128.
35. Bucher H C, Griffith L E, Guyatt G H, et al. Isoniazid prophylaxis for tuberculosis in HIV infection: a meta-analysis of randomized controlled trials. AIDS 1999; 13: 501-507.